<DOC>
	<DOC>NCT02570191</DOC>
	<brief_summary>This study will evaluate the efficacy, safety, and tolerability of PEGASYS in participants with HBeAg-negative chronic HBV. The anticipated time on study treatment is 48 weeks, and the target sample size is 60 individuals.</brief_summary>
	<brief_title>A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult participants 1870 years of age Positive test result for HBsAg for &gt;6 months Naive to treatment for HBV On liver biopsy, liver disease consistent with chronic HBV, with or without compensated cirrhosis Coinfection with hepatitis A, C or D, or with Human Immunodeficiency Virus (HIV) Decompensated liver disease Hepatocellular cancer Systemic antiviral, antineoplastic, or immunomodulatory therapy less than or equal to 6 months before study drug Medical condition associated with chronic liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>